PTH is a critical regulator of skeletal development that promotes both bone formation and bone resorption. Using microbiota depletion by wide-spectrum antibiotics and germ-free (GF) female mice we showed that the microbiota was required for PTH to stimulate bone formation and increase bone mass. Microbiota depletion lowered butyrate levels, a metabolite responsible for gut-bone communication, while reestablishment of physiologic levels of butyrate restored PTH-induced anabolism. The permissive activity of butyrate was mediated by GPR43 signaling in dendritic cells (DCs) and by GPR43-independent signaling in T cells. Butyrate was required for PTH to increase the number of bone marrow (BM) regulatory T cells (Tregs). Tregs stimulated production of the osteogenic Wnt ligand Wnt10b by BM CD8 + T cells, which activated Wnt dependent bone formation. Together, these data highlight the role that butyrate produced by gut luminal microbiota plays in triggering regulatory pathways which are critical for the anabolic action of PTH in bone.
INTRODUCTION
Parathyroid hormone (PTH) is a calciotrophic hormone produced by the parathyroid glands.
PTH is a critical regulator of skeletal development and postnatal skeletal maturation due to its capacity to stimulate both bone formation and bone resorption (1) . Accordingly, lack of PTH leads to decreased trabecular bone in fetal and neonatal mice (2) . PTH may induce bone loss or promote bone mass acquisition, mainly depending on whether target cells are exposed to PTH continuously or intermittently. The bone catabolic activity of PTH is most pronounced when the hormone is produced or infused in excessive amounts and in a continuous fashion (3), as it happens in primary and secondary hyperparathyroidism (4) . In these conditions PTH stimulates bone resorption and, to a lesser extent, bone formation leading to net bone loss (5, 6) . While stimulation of bone formation is a constant response elicited by PTH, the bone anabolic activity of PTH is maximized by daily injections of PTH in young mice, a treatment modality known as intermittent PTH (iPTH) treatment. This intervention markedly increases bone volume and strength due to a stimulation of bone formation tempered by a more moderate increase in resorption (6, 7) . Stimulation of bone formation is due to increased osteoblast formation and lifespan and reactivation of bone lining cells. These effects of iPTH are secondary to activation of Wnt signaling in osteoblastic cells (7, 8) .
In the mouse iPTH activates Wnt signaling through multiple mechanisms including blunted osteocytic production of the Wnt inhibitor sclerostin (9) (10) (11) and decreased production by osteoblasts of the Wnt inhibitor Dkk1 (12) . These effects result from direct activation of the PTH/PTHrP receptor in osteoblasts and osteocytes (13, 14) . In addition, reports in humans and animals show that Teriparatide activates Wnt signaling by inducing the production of Wnt10b, an osteogenic Wnt ligand produced by T cells (15) (16) (17) (18) . Animal studies further show that the relevant pool of Wnt10b derives from BM CD8 + T cells (16) (17) (18) . Accordingly, global or T cell specific silencing of Wnt10b production blocks the capacity of iPTH to increase bone formation 4 and trabecular bone volume (16) (17) (18) . By contrast, the anabolic effects of iPTH in cortical bone are completely T cell independent (16) (17) (18) , likely due to the fact that T cells have no contacts with periosteal surfaces and have limited capacity to communicate with osteocytes.
iPTH cause a ~2-3-fold increase in the number of Tregs in humans and mice, which is required for iPTH to exert its bone anabolic activity (19) . Tregs are suppressive helper CD4 + T cells that play an essential role in dampening inflammation and maintaining immune tolerance (20) . Reports have highlighted the bone regulating capacities of Tregs, describing mechanisms where Tregs blunt bone resorption (21, 22) , stimulate bone formation by promoting the differentiation of osteoblasts (23) , and are pivotal for the stimulation of bone formation induced by nutritional supplementation with the probiotic Lactobacillus rhamnosus GG (LGG) (24, 25) .
The enzymatic activity harbored within some taxa of gut microbiota can digest carbohydrates to generate millimolar concentrations of the SCFAs butyrate, propionate, and acetate (26) .
SCFAs selectively support the development of peripheral Tregs (27) (28) (29) . This suggests that microbiota-induced generation of SCFAs in the gut may promote Treg differentiation in BM, which is pivotal for the bone anabolic activity of iPTH.
Here we examined the role of the microbiota and of butyrate in the regulation of bone responses to iPTH in young female mice. We report that the activity of iPTH is blocked in mice lacking or depleted of the microbiota, or the SCFA receptor GPR43, and that in microbiota depleted mice the activity of iPTH is reestablished by restoration of permissive amounts of circulating butyrate.
RESULTS iPTH treatment does not induce bone anabolism in germ-free mice and antibiotic treated conventional mice
To investigate the role of the microbiota in the bone anabolic activity of PTH, C57BL6 female mice were raised in either conventional conditions (Conv.R mice), or GF conditions (GF mice) and treated with vehicle or iPTH for 4 weeks, starting at the age of 8 weeks. Analysis by in vitro µCT of femurs harvested at 12 weeks of age revealed that iPTH increased trabecular bone volume fraction (BV/TV) and trabecular thickness (Tb.Th) in Conv.R mice but not in GF mice (Figure 1A-C) . Trabecular number (Tb.N), and trabecular separation (Tb.Sp), which are additional indices of trabecular structure, were altered by iPTH in Conv. R. controls but not in GF mice (SF1A,B). To confirm the relevance of the microbiota for the bone anabolic activity of PTH, in a second experiment Conv. R mice were treated with vehicle or iPTH for 4 weeks starting at the age of 8 weeks, and either with or without broad-spectrum antibiotics (1 mg/mL ampicillin, 0.5 mg/mL vancomycin, 1 mg/mL neomycin sulfate, 1 mg/mL metronidazole, dissolved in water) for 6 weeks, starting at the age of 6 weeks. Treatment with antibiotics decreased gut bacterial load by > 99 % (SF2). iPTH increased BV/TV and Tb.Th in control Conv. R. mice but not in those treated with antibiotics (Figure 1D-F) . Similarly, iPTH increased Tb.N and decreased Tb.Sp in control Conv.R mice, while it was ineffective in antibiotic treated mice (SF1C,D). Analysis of cortical structure by µCT revealed that iPTH increased cortical area (Ct.Ar) and cortical thickness (Ct.Th), in control Conv. R. mice as well as GF mice, and Conv. R. antibiotic treated mice (Figure 1G-J) . Together these findings indicate that the microbiome is required for the anabolic activity of iPTH in trabecular bone, but it is not implicated in the mechanism whereby iPTH increases cortical bone mass.
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To investigate the role of the microbiome in the skeletal response to iPTH of older mice, Conv.R mice were treated with vehicle or iPTH and either with or without antibiotics for 4 weeks, starting at 6 months of age. Control mice treated with vehicle had a lower BV/TV than the corresponding group of antibiotic treated mice, reflecting the life-long pro-resorptive effect of the microbiota. Confirming a requirement for the microbiota, iPTH increased BV/TV and Tb.Th in control mice but not in mice treated with antibiotics ( Figure 1K,L) . As a result, control mice and antibiotic treated mice treated with iPTH had a similar BV/TV ratio. Similarly, iPTH increased Tb.N and decreased Tb.Sp in control mice, while it was ineffective in antibiotic treated mice
(SF1E,F).
Analysis of femurs harvested at 12 weeks of age by histomorphometry revealed that iPTH increased the dynamic indices of bone formation mineral apposition rate (MAR) and bone formation rate (BFR/BS) in the trabecular compartment of Conv.R mice, but not of GF mice ( Figure 2K-P) . These data indicate that the microbiota is required for iPTH to increase formation and resorption in cancellous bone. By contrast, iPTH increase cortical MAR and cortical BFR/BS in control and antibiotic treated Conv.R. mice, confirming that the microbiota is not required for the anabolic activity of iPTH in cortical bone
Figure 2Q,R).
Measurements of serum levels of osteocalcin, a marker for bone formation revealed that iPTH increased osteocalcin levels in all groups of 12-week-old mice, although to a lesser degree in mice lacking the microbiome (Figure S3A,B) . Serum CTX, a marker for bone resorption, also increased significantly in response to iPTH in all groups of mice (Figure S3C,D) . These findings are in agreement with the fact that osteocalcin and CTX reflect primarily cortical bone turnover.
To determine the role of the microbiome on osteoblastogenesis, BM was harvested at 12 weeks of age and cultured for 1 week, and stromal cells (SCs) purified and used to determine their rate of proliferation and apoptosis as previously described (16, 18, 19) . These experiments revealed that iPTH failed to increase the proliferation of SCs from GF mice or Conv. R. mice treated with antibiotics, while it stimulated SC proliferation in microbiota replete groups ( Figure   3A ,B). Moreover, iPTH had no effects on the rate of SC apoptosis in GF mice or antibiotic treated Conv. R. mice, while it decreased SC apoptosis in control Conv. R. mice (Figure 3C,D) .
Analysis of the expression levels of osteoblast differentiation genes in SCs revealed that iPTH treatment increased the expression of type 1 collagen, Runx2, Osterix, Bone Sialoprotein, and Osteocalcin mRNAs in SCs from microbiota replete mice while it had no effect on SCs from mice raised in GF conditions and in SCs from antibiotic treated Conv. R. mice ( Figure 3E,F) .
These findings demonstrate that iPTH regulates osteoblast proliferation, differentiation and life span through a microbiome dependent mechanism.
Because osteoblast proliferation and differentiation are induced by activation of canonical Wnt signaling (32), we measured transcript enrichment of genes upregulated in response to Wnt signaling. Transcript levels of nine measured Wnt-responsive genes were increased by iPTH in SCs of control mice, but not in SCs from GF mice or from antibiotic treated Conv. R. mice ( Figure 3G,H) , indicating that iPTH activated Wnt signaling in SCs through a microbiota dependent mechanism.
Previous reports demonstrate that CD8 + T cell produced Wnt10b is critical for the anabolic activity of iPTH in the trabecular compartment of the skeleton (16) (17) (18) . Therefore, we 8 investigated whether the microbiome is required for iPTH to upregulate Wnt10b expression.
iPTH increased Wnt10b transcripts in whole BM cells and BM CD8 + T cells from microbiota replete mice, but not in those from GF mice and antibiotic treated Conv. R. mice ( Figure 3I-L) .
iPTH increases the number of BM Tregs in humans and mice (19) . This effect is critical for the bone anabolic activity of iPTH, as an increase in the number of Tregs is required for iPTH to induce production of Wnt10b by BM CD8 + T cells (19) . The microbiota controls the induction and maintenance of colonic Tregs, via multiple mechanisms (33) , suggesting that the microbiota might not only be required for the generation of intestinal Tregs in unstimulated conditions, but also for iPTH to expand Tregs. We used flow cytometry to test this hypothesis. Since the calculation of the absolute number of PP Tregs is technically challenging due to variability of the size of the collected PP tissue, PP Tregs cells were quantified only as percentage of total CD4 + T cells. We found that iPTH treatment increased the number of Peyer's patches (PP) Tregs and BM Tregs in microbiota replete mice, but not in GF mice and antibiotic treated Conv.R. mice TGFb1 and IGF-1 are factors capable of promoting Tregs differentiation (33) (34) (35) induced by iPTH (36) (37) (38) . In this study we assessed the role of the microbiome on the capacity of iPTH to stimulate the production of TGFb1 and IGF-1 in the BM. iPTH treatment increased Tgfb1 and Igf1 transcripts in the BM of microbiota replete Conv. R. mice but not in the BM of GF mice and Conv. R. mice treated with antibiotics ( Figure 3Q-T) . These findings indicate that the microbiota is required for iPTH to increase the production of TGFb1 and IGF-1 in the BM.
Gut microbiota production of butyrate enables iPTH to promote bone anabolism
Butyrate and other SCFAs, produced in the murine cecum and human colon by bacterial fermentation of non-digestible material (39) , play a central role in the differentiation of colonic Tregs through actions on dendritic cells (DCs) and naïve CD4 + T cells (27) (28) (29) .
We investigated the hypothesis that the microbiota produces permissive levels of SCFAs that are required for iPTH to expand Tregs and induce bone anabolism. Serum levels of butyrate were lower in antibiotic treated Conv. R. mice than in mice not treated with antibiotics ( Figure   4A ), indicating that the microbiota contributed to the generation of circulating butyrate. In antibiotic treated mice, nutritional supplementation with butyrate (5 mM) increased serum butyrate to levels similar to those measured in mice not treated with antibiotics ( Figure 4A) .
Moreover, butyrate supplementation restored the capacity of iPTH to increase BV/TV and Tb.Th (Figure 5A ). Propionate and acetate did not increase Treg differentiation in cultures of WT naïve CD4 + T cells, whereas a mixture of all three SCFAs was as effective as butyrate alone (Figure 5B) . These findings confirmed that butyrate has the capacity of directly targeting CD4 + T cells (27) . In vitro butyrate treatment increased the transcript levels of the Treg-inducing factors Tgfb1 and Igf1 in cultures of WT BM cells ( Figure   5C ,D), indicating that butyrate may also potentiate Treg differentiation indirectly. By contrast, PTH failed to increase Treg differentiation when added to cultures of WT naïve CD4 + T cells ( Figure 5E ), indicating that PTH did not directly targeted CD4 + T cells.
We also found an increase in Treg differentiation in anti-CD3 antibody and TGFb-stimulated cocultures of DCs perpetrated in vitro with butyrate for 6 hours and untreated CD4 + T cells ( Figure 5F) . By contrast, pretreatment of DCs with PTH was ineffective ( Figure 5G) . These findings are consistent with the notion that targeting of DCs is one of the mechanisms by which butyrate induces Treg differentiation (27) . The data also indicate that PTH did not directly targeted DCs.
To further investigate cellular targets of butyrate and PTH relevant for Treg differentiation, 8- week-old Conv. R. mice were treated with antibiotics for 4 weeks to dampen butyrate levels.
These mice were also treated with vehicle, iPTH or butyrate for the last 2 weeks of the experiment. DCs and naïve CD4 + T cells were sorted and cocultured in the presence of anti-CD3 antibody and TGFb. In this ex-vivo assay, cocultures of DCs from butyrate treated mice and CD4 + T cells from either iPTH treated or butyrate treated mice were the most efficient in generating Tregs (Figure 5H) . A smaller yet significant increase in Treg differentiation was also detected in all the other groups except cocultures of DCs from iPTH treated mice and T cells from vehicle treated mice. These data suggested that butyrate affects both T cells and DCs while iPTH regulates T cells but not DCs. Because in vitro treatment with PTH did not stimulate Treg differentiation ( Figure 5E ), iPTH is likely to affect T cells indirectly. Since the effects of butyrate on DCs and CD4 + T cells were only partially additive, the signaling events activated by butyrate in these two cell lineages are likely to converge on a common downstream target.
iPTH expands Tregs through a GPR43 mediated mechanism

Butyrate induces Treg differentiation primarily via T cell intrinsic epigenetic regulation of the
Foxp3 gene (28) . An additional means of Treg induction by SCFAs is the activation of the cell surface signaling receptor GPR43 (29, 40) . To investigate the specific mechanisms involved, 8- week-old female GPR43-/-mice and WT littermates were treated with iPTH for 4 weeks.
Analysis by in vitro µCT of femurs harvested at sacrifice revealed that iPTH increased BV/TV and improved indices of trabecular structure in GPR43+/+ mice but not in GPR43-/-mice ( Figure 6A,B and SF5A,B) . In GPR43-/-mice, iPTH also failed to increase serum osteocalcin and CTX levels (Figure 6C,D GPR43 signaling in T cells and/or DCs could be necessary for iPTH to expand Tregs. To investigate the role of GPR43 signaling in T cells, TCRb-/-mice, a strain completely devoid of ab T cells, were reconstituted with sorted splenic T cells from GPR43-/-mice or GPR43+/+ littermates. Two weeks post adoptive transfer, which is a period sufficient for engraftment and expansion of T cells (24) , all mice were treated with either vehicle or iPTH for 4 weeks. iPTH increased BV/TV and Tb.Th, as well as osteocalcin and CTX levels in mice reconstituted with GPR43-/-T cells and in those reconstituted with GPR43+/+ T cells (Figure 7A-D) . In addition, iPTH expanded PP and BM Tregs (Figure 7E,F 
), and increased BM and CD8 + T cells levels of
Wnt10b transcripts in all mice ( Figure 7G,H) . These findings indicated that GPR43 signaling in T cells was not required for iPTH to induce bone anabolism. This hypothesis was confirmed by the finding that in vitro treatment with butyrate dose-dependently increased the formation of Tregs in cultures of GPR43-/-and GPR43+/+ naive CD4 + T cells (Figure 7I ).
Since GPR43 expression is restricted to myeloid cells among hematopoietic cells (41) , and considering that butyrate potentiates the capacity of DCs to induce Treg differentiation (27) , 
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DISCUSSION
We reported that the production of permissive amounts of butyrate from the gut microbiota was required for iPTH to induce bone anabolism in young female mice. Microbial production of butyrate potentiated the capacity of iPTH to induce the differentiation of naïve CD4 + T cells into Tregs, a population of T cells which induces conventional CD8 + T cells to release Wnt10b. This osteogenic Wnt ligand activates Wnt signaling in osteoblastic cells and stimulate bone formation (16) (17) (18) . Butyrate enable iPTH to expand Tregs via GPR43 signaling in DCs and GPR43 independent targeting of T cells. Whether this mechanism is sex-dependent remains to be determined.
Tregs are a population of predominantly CD4 + T cells that play a critical role in maintaining immune tolerance and immune homeostasis (20) . Tregs are also recognized as important bone regulators. Tregs reside preferentially on the endosteal surfaces of bone (42) , where they regulate osteoclast formation (21, 22, 43) , blunt bone resorption (21, 44) , and prevent ovariectomy induced bone loss (45) . In addition, Tregs are recognized as mediators of the bone anabolic activity of the probiotic LGG (24, 25) and of iPTH (19) . Supporting a role for Tregs in the skeletal activity of iPTH are reports that blockade of Treg expansion silences the bone anabolic activity of PTH (19) .
The intestinal microbiota controls the induction and maintenance of intestinal Tregs via multiple mechanisms, including costimulation of naïve CD4 + T cells by DCs activated by
bacterial antigens (46) , signals from Toll-like receptors (TLRs) and other microbial pattern recognition molecules (47), IL-2 produced by T cells activated by bacterial antigens (48) , TGFb, IGF-1, retinoic acid, and a number of additional microbiota-derived, host cell-derived, and dietderived factors (33) . In addition, the intestinal microbiota promotes Treg differentiation in distant organs via SCFAs derived from bacterial fermentation of complex non-digestible carbohydrates present in the diet (33, 49) .
In the current study we found antibiotic treatment to decrease the circulating levels of butyrate by ~50 % and to block the expansion of intestinal and BM Tregs induced by iPTH. The capacity of iPTH to expand Tregs was reestablished by supplementation with a dose of butyrate which restored physiologic circulating levels of butyrate. Based on these findings we concluded that permissive levels of butyrate were required for iPTH to regulate Treg differentiation.
The mechanism by which SCFAs expand Tregs has been extensively investigated (27) (28) (29) .
SCFAs induce the differentiation of naive CD4 + T cells into Tregs via histone H3 acetylation of CNS1 of Foxp3 by HDAC inhibition through a receptor-independent mechanism (28) . Moreover, SCFAs stimulate Treg proliferation through activation of GPR43 (29) . Additional effects of SCFAs on Treg maturation are mediated by DCs (27) . One report linked this effect to activation of the SCFA receptor GPR109A in DCs (50), while another did not confirm a role for GR109A and ascribed the activating effects of butyrate on DCs to HDAC inhibition (27) . In line with these reports (27) , in vitro studies revealed that butyrate was capable of increasing Treg differentiation by targeting directly T cells and DCs, while PTH was not. However, more physiologic ex-vivo studies conducted by co-culturing DCs and T cells harvested from mice treated in vivo with butyrate or iPTH revealed that the most relevant effect of butyrate was to increase the capacity of DCs to support Treg differentiation, while iPTH contributed to Treg differentiation by affecting CD4 + T cells through an indirect mechanism that remains to be determined. These findings were corroborated by data that showed that iPTH failed to induce bone anabolism and expand Tregs in GPR43-/-mice. The expression of GPR43 is restricted to myeloid cells including DCs (28) , confirming that PTH requires butyrate-induced DC activation to expand Tregs. On the other hand, maintenance of Tregs in unstimulated conditions was microbiota dependent but GPR43 independent, as GF and antibiotic treated conventional mice had fewer intestinal and BM Tregs than microbiota replete mice, while GPR43-/-and WT littermates had similar number of Tregs.
While depletion of the microbiota completely abrogated the bone anabolic activity of iPTH, conditional deletion of the PTH-PTHrP receptor in T cells blunts but does not abolish the anabolic activity of iPTH (17) . These data further attest to the relevance of DCs as targets of butyrate and suggest that additional microbial products may mediate the effects of iPTH on targets other than T cells. Among the factors recognized to mediate the effects of iPTH on osteoblasts and to be microbial dependent is IGF-1 (51) , which is also the first metabolite identified as a linker in the gut-bone axis (31, 52) . Another bone-regulating molecule that could be permissive for the activity of iPTH is hydrogen sulfide, a gasotransmitter generated by bacteria residing within the gut (53, 54)that stimulates bone formation and postnatal skeletal development (55) .
The bone histomorphometric analysis conducted in the current study revealed that ablation of the microbiota blocked not only the effects of iPTH on bone formation, but also those on trabecular bone resorption. It is unlikely that butyrate may enhance the pro-resorptive activity of iPTH, as butyrate directly inhibits osteoclastogenesis and bone resorption (56) . Also unlikely is the possibility that iPTH may stimulate bone resorption through T cell produced Wnt10b, as silencing of Wnt10b expression in T cells does not block iPTH induced bone resorption (16) . By contrast, deletion of T cells blocks iPTH -induced bone resorption (16) . Since iPTH decreases the expression of the antiosteoclastogenic factor IFNg by BM T cells (19) and considering that the microbiome regulates T cell expression of IFNg (57, 58) , it is likely that the microbiome is required for iPTH to blunt IFNg production and thus stimulate bone resorption.
The bone anabolic activity of iPTH is, in part, mediated by PTH binding to the PTH/PTHrP receptor in osteocytes and the resulting blockade of the osteocytic production of the Wnt inhibitors sclerostin and Dkk1 (10) (11) (12) . Importantly, deletion of PTH/PTHrP in osteocytes blocks the bone anabolic activity of iPTH (13, 14) as effectively as depletion of the microbiota. This is consistent with a model where independent and parallel activation of Wnt signaling by PTH binding to the PTH/PTHrP receptor in osteocytes and the microbiota/butyrate/Wnt10b pathway are both required for iPTH to stimulate bone formation.
The mechanism of action of iPTH described herein is surprisingly similar to the mechanism by which nutritional supplementation with the probiotic LGG stimulates bone formation and increase bone volume (24, 25) . Tregs stimulate Wnt10b gene expression in CD8 + T cells by silencing CD28 signaling, an event that lowers the production of AP-1 by CD8 + T cells and shifts the associations of NFAT to SMADs rather than AP-1 (24) . This increases the binding of NFAT/SMAD dimers to a transcription-activating binding sites located between -705 bp and -272 bp in the Wnt10b promoter (24) . In mice treated with LGG the recruitment of NFAT to the Wnt10b promoter is directly increased by butyrate. By contrast, in mice with physiologic levels of butyrate, it is likely that iPTH contributes to NFAT translocation by directly targeting CD8 + T cells, as PTH and PTHrP have previously been shown to directly activate NFAT signaling in other cell lineages (59, 60) .
Osteoporosis is a common chronic disorder that represents a major source of disability in the elderly. An increase in the number of Tregs achievable by nutritional supplementation with butyrate may represent a novel therapeutic modality for osteoporosis or for potentiating the bone anabolic activity of PTH. Moreover, the use of butyrate to increase the number of Tregs may find wider applications, such as in transplant medicine or as a treatment for inflammatory and autoimmune conditions.
MATERIAL AND METHODS
Animals. All in vivo experiments were carried out in female mice. Conventionally raised C57BL6 WT mice and C57BL6 TCRb-/-mice were acquired from Jackson Laboratories (Bar Harbor, ME). C57BL6 GPR43-/-mice were supplied by Amgen (Thousand Oaks, CA). All mice were maintained under specific pathogen free conditions and fed sterilized food (5V5R chow) and autoclaved water ad libitum. 6 weeks old female C57BL6 Germ Free (GF) mice were purchased from Taconic biosciences (Rensselaer, NY). Experimental GF mice were maintained in a Tecniplast ISOcage P -Bioexclusion System under strict 12 hours light cycle and fed with autoclaved chow diet ad libitum within the Emory Gnotobiotic Animal Core (EGAC).
In vivo iPTH treatment. For the in vivo iPTH studies, 80 µg/kg/day of hPTH 1-34 (Bachem California Inc., Torrance, CA) or vehicle was injected daily subcutaneously into female mice for 4 weeks starting at the age of 8 weeks or at the age of 6 months, as described (16) (17) (18) 61) .
Antibiotics and Butyrate treatment. For antibiotic treatment, mice were given broadspectrum antibiotics (1 g/L metronidazole, 1 g/L ampicillin, 1 g/L neomycin sulfate, and 0.5 g/L vancomycin, Millipore-Sigma, St. Louis, MO) in drinking water. Depletion of microbiota was verified by quantitative real-time PCR using universal primers 16S rRNA. For butyrate administration, mice were treated with broad-spectrum antibiotics for 2 weeks, followed by supplementing 5 mM butyrate in the antibiotic water for another 4 weeks. PTH or vehicle were injected into mice daily for 4 weeks starting at 2 weeks after the antibiotic treatment.
Excision of Peyer's patches (PP) from small intestine and preparation of single cell suspension by mechanical dissociation
Peyer's patches (PP) cell isolation was performed as described (62) . Briefly, the small intestine was removed and flushed of fecal content. PPs were excised and collected in 1 ml cooled RPMI1640. PPs were dissociated using the plunger of a 2.5 ml syringe and gently forced 18 through a 70 µm cell strainer placed over a 50 ml tube. A single cell suspension was used for analysis by flow cytometry. µCT measurements. μCT scanning and analysis was performed using a Scanco μCT-40 scanner, as previously reported (18, 63, 64) . Settings used for the in vitro scans are as follows: 70kVp 114uA, 8W with an integration time of 200ms with a voxel size of 12 μm 3 for femurs from 12-week-old mice, and a voxel size of 10.5 μm 3 for femurs from 7-month-old mice. For the femoral trabecular region, we analyzed 70 slices, beginning 50 slices from the distal growth plate. Femoral cortical bone was measured using 80 continuous CT slides located at the femoral midshaft. We used the thresholding approach described by Bouxsein et al (65) , which is recommended by Scanco, which includes a visual inspection and comparison of preview and slice-wise grey scale 2D images. The same threshold value was used for all measurements.
Quantitative bone histomorphometry. The measurements, terminology and units used for histomorphometric analysis, were those recommended by the Nomenclature Committee of the American Society of Bone and Mineral Research (66) . Mice were injected subcutaneously with calcein at day 7 and day 2 before sacrifice. Non-consecutive longitudinal sections of the femur (5 µm thick) were cut from methyl methacrylate plastic-embedded blocks along the frontal plane using a Leica RM2155 microtome as described previously (63) and stained with Goldner's trichrome stain for the static measurements. Additional sections were cut at 10 μm and left unstained for dynamic (fluorescent) measurements. Trabecular measurements were obtained in an area of cancellous bone that measured ~2.5 mm 2 and contained only secondary spongiosa, which was located 0.5-2.5 mm proximal to the epiphyseal growth cartilage of the femurs. 
Butyrate quantification in serum samples. Measurement of butyrate levels was done by
the Emory Integrated Lipidomics Core (EILC). SCFAs extraction and derivation of serum samples were performed as described (24) . Serum butyrate levels were measured by the internal standard method using the ExionLC AC system coupled to triple quadrupole mass spectrometer QTRAP5500 (ABSciex, Framingham, MA). Peak determination, peak area integration and calibration curves for standards were performed with the MultiQuant 3. 
